60 related articles for article (PubMed ID: 9413147)
1. Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory JG; Cory AH; Lorico A; Rappa G; Sartorelli AC
Anticancer Res; 1997; 17(5A):3185-93. PubMed ID: 9413147
[TBL] [Abstract][Full Text] [Related]
2. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
3. Mouse leukemia L1210 cells selected for resistance to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone show altered response to DNA damaging agents.
Crenshaw TR; Cory JG
Int J Oncol; 1999 Sep; 15(3):487-90. PubMed ID: 10427129
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
Rappa G; Lorico A; Liu MC; Kruh GD; Cory AH; Cory JG; Sartorelli AC
Biochem Pharmacol; 1997 Sep; 54(6):649-55. PubMed ID: 9310341
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
7. In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Somerville L; Cory AH; Cory JG
In Vivo; 2002; 16(3):175-7. PubMed ID: 12182112
[TBL] [Abstract][Full Text] [Related]
8. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of protein disulfide isomerase-like protein in a mouse leukemia L1210 cell line selected for resistance to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, a ribonucleotide reductase inhibitor.
Crenshaw TR; Cory JG
Adv Enzyme Regul; 2002; 42():143-57. PubMed ID: 12123712
[No Abstract] [Full Text] [Related]
10. Liver microsomal inactivation of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone as an inhibitor of ribonucleotide reductase.
Williams MT; Simonet L; Cory AH; Cory JG
Cancer Res; 1988 Nov; 48(22):6375-8. PubMed ID: 3052801
[TBL] [Abstract][Full Text] [Related]
11. 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, a second-generation antineoplastic agent of the alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazone series.
Agrawal KC; Schenkman JB; Denk H; Mooney PD; Moore EC; Wodinsky I; Sartorelli AC
Cancer Res; 1977 Jun; 37(6):1692-6. PubMed ID: 870183
[TBL] [Abstract][Full Text] [Related]
12. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells.
Breier A; Drobná Z; Barancík M
Neoplasma; 1998; 45(4):248-53. PubMed ID: 9890669
[TBL] [Abstract][Full Text] [Related]
13. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake.
Shen DW; Goldenberg S; Pastan I; Gottesman MM
J Cell Physiol; 2000 Apr; 183(1):108-16. PubMed ID: 10699972
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the multixenobiotic resistance (MXR) mechanism in embryos and larvae of the zebra mussel (Dreissena polymorpha) and studies on its role in tolerance to single and mixture combinations of toxicants.
Faria M; Navarro A; Luckenbach T; Piña B; Barata C
Aquat Toxicol; 2011 Jan; 101(1):78-87. PubMed ID: 20947180
[TBL] [Abstract][Full Text] [Related]
15. Reduction of doxorubicin resistance by tetrandrine and dauricine in harringtonine-resistant human leukemia (HL60) cells.
He QY; Meng FH; Zhang HQ
Zhongguo Yao Li Xue Bao; 1996 Mar; 17(2):179-81. PubMed ID: 9772674
[TBL] [Abstract][Full Text] [Related]
16. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux.
Chau M; Christensen JL; Ajami AM; Capizzi RL
Leuk Res; 2008 Mar; 32(3):465-73. PubMed ID: 17826829
[TBL] [Abstract][Full Text] [Related]
17. Modulation of methotrexate resistance by genistein in murine leukemia L1210 cells.
Xuan Y; Hacker MP; Tritton TR; Bhushan A
Oncol Rep; 1998; 5(2):419-21. PubMed ID: 9468571
[TBL] [Abstract][Full Text] [Related]
18. Effects of the ferrous chelate of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIQ-1) on the kinetics of reduction of CDP by ribonucleotide reductase of the Novikoff tumor.
Preidecker PJ; Agrawal KC; Sartorelli AC; Moore EC
Mol Pharmacol; 1980 Nov; 18(3):507-12. PubMed ID: 7007866
[No Abstract] [Full Text] [Related]
19. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
[TBL] [Abstract][Full Text] [Related]
20. Schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia.
Gale GR; Atkins LM; Meischen SJ; Schwartz P
Cancer Treat Rep; 1979 Mar; 63(3):449-56. PubMed ID: 427825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
